GENMAB A/S -SP ADR (GMAB)
US3723032062 - ADR
Overall GMAB gets a fundamental rating of 7 out of 10. We evaluated GMAB against 571 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: GMAB is growing strongly while it also seems undervalued. With these ratings, GMAB could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
In the past year GMAB had a positive cash flow from operations.
Each year in the past 5 years GMAB has been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
1.2 Ratios
GMAB's Return On Assets of 14.25% is amongst the best of the industry. GMAB outperforms 97.88% of its industry peers.
Looking at the Return On Equity, with a value of 17.77%, GMAB belongs to the top of the industry, outperforming 97.18% of the companies in the same industry.
GMAB's Return On Invested Capital of 13.65% is amongst the best of the industry. GMAB outperforms 96.65% of its industry peers.
GMAB had an Average Return On Invested Capital over the past 3 years of 13.32%. This is in line with the industry average of 13.56%.
The 3 year average ROIC (13.32%) for GMAB is below the current ROIC(13.65%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.25% | ||
| ROE | 17.77% | ||
| ROIC | 13.65% |
ROA(3y)14.15%
ROA(5y)15.85%
ROE(3y)15.69%
ROE(5y)17.48%
ROIC(3y)13.32%
ROIC(5y)15.82%
1.3 Margins
GMAB has a Profit Margin of 29.01%. This is amongst the best in the industry. GMAB outperforms 98.41% of its industry peers.
GMAB's Profit Margin has declined in the last couple of years.
GMAB's Operating Margin of 31.65% is amongst the best of the industry. GMAB outperforms 98.94% of its industry peers.
In the last couple of years the Operating Margin of GMAB has declined.
With an excellent Gross Margin value of 96.83%, GMAB belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.65% | ||
| PM (TTM) | 29.01% | ||
| GM | 96.83% |
OM growth 3Y-19.72%
OM growth 5Y-6.68%
PM growth 3Y-17.51%
PM growth 5Y-11.5%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
Compared to 1 year ago, GMAB has about the same amount of shares outstanding.
GMAB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GMAB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 9.57 indicates that GMAB is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.57, GMAB belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
The Debt to FCF ratio of GMAB is 0.16, which is an excellent value as it means it would take GMAB, only 0.16 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GMAB (0.16) is better than 97.35% of its industry peers.
GMAB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GMAB (0.03) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.16 | ||
| Altman-Z | 9.57 |
ROIC/WACC2.03
WACC6.72%
2.3 Liquidity
GMAB has a Current Ratio of 5.03. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a Current ratio of 5.03. This is comparable to the rest of the industry: GMAB outperforms 54.67% of its industry peers.
GMAB has a Quick Ratio of 5.02. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a Quick ratio (5.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 5.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.57% over the past year.
Measured over the past years, GMAB shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.70% on average per year.
GMAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.57%.
The Revenue has been growing by 40.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.57%
EPS 3Y-2.95%
EPS 5Y22.7%
EPS Q2Q%-38.71%
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y40.35%
Sales Q2Q%16.78%
3.2 Future
Based on estimates for the next years, GMAB will show a very strong growth in Earnings Per Share. The EPS will grow by 23.65% on average per year.
GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.51% yearly.
EPS Next Y30.61%
EPS Next 2Y22.39%
EPS Next 3Y23.56%
EPS Next 5Y23.65%
Revenue Next Year28.56%
Revenue Next 2Y22.38%
Revenue Next 3Y19.9%
Revenue Next 5Y17.51%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GMAB is valuated rather expensively with a Price/Earnings ratio of 20.25.
Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.94% of the companies listed in the same industry.
GMAB is valuated rather cheaply when we compare the Price/Earnings ratio to 29.29, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 14.64, the valuation of GMAB can be described as correct.
GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.12% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.01. GMAB is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.25 | ||
| Fwd PE | 14.64 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.35% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.18% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.42 | ||
| EV/EBITDA | 10.77 |
4.3 Compensation for Growth
GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GMAB has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GMAB's earnings are expected to grow with 23.56% in the coming years.
PEG (NY)0.66
PEG (5Y)0.89
EPS Next 2Y22.39%
EPS Next 3Y23.56%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENMAB A/S -SP ADR
NASDAQ:GMAB (11/22/2024, 8:00:00 PM)
After market: 20.65 0 (0%)20.65
+0.18 (+0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.11B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.25 | ||
| Fwd PE | 14.64 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.66
PEG (5Y)0.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.25% | ||
| ROE | 17.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 31.65% | ||
| PM (TTM) | 29.01% | ||
| GM | 96.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.03 | ||
| Quick Ratio | 5.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)9.57%
EPS 3Y-2.95%
EPS 5Y
EPS Q2Q%
EPS Next Y30.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.57%
Revenue growth 3Y17.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y